278 related articles for article (PubMed ID: 37735815)
1. Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets.
Alahdal M; Elkord E
Clin Transl Med; 2023 Sep; 13(9):e1425. PubMed ID: 37735815
[TBL] [Abstract][Full Text] [Related]
2. H1Innovative approaches to combat anti-cancer drug resistance: Targeting lncRNA and autophagy.
Zhong C; Xie Z; Duan S
Clin Transl Med; 2023 Oct; 13(10):e1445. PubMed ID: 37837401
[TBL] [Abstract][Full Text] [Related]
3. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
4. Cytological effects of honokiol treatment and its potential mechanism of action in non-small cell lung cancer.
Zhang J; Zhang Y; Shen W; Fu R; Ding Z; Zhen Y; Wan Y
Biomed Pharmacother; 2019 Sep; 117():109058. PubMed ID: 31176168
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
6. Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer.
Cao B; Liu M; Wang L; Zhu K; Cai M; Chen X; Feng Y; Yang S; Fu S; Zhi C; Ye X; Zhang J; Zhang Z; Yang X; Zhao M; Wu Q; Xu L; Yang L; Lian H; Zhao Q; Zhang Z
Nat Commun; 2022 Oct; 13(1):6203. PubMed ID: 36261437
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy.
Xue T; Zhao X; Zhao K; Lu Y; Yao J; Ji X
Curr Probl Cancer; 2022 Feb; 46(1):100791. PubMed ID: 34538649
[TBL] [Abstract][Full Text] [Related]
8. Single bioengineered ncRNA molecule for dual-targeting toward the control of non-small cell lung cancer patient-derived xenograft tumor growth.
Petrek H; Yan Ho P; Batra N; Tu MJ; Zhang Q; Qiu JX; Yu AM
Biochem Pharmacol; 2021 Jul; 189():114392. PubMed ID: 33359565
[TBL] [Abstract][Full Text] [Related]
9. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.
Liu D; Badeti S; Dotti G; Jiang JG; Wang H; Dermody J; Soteropoulos P; Streck D; Birge RB; Liu C
Cell Commun Signal; 2020 Aug; 18(1):134. PubMed ID: 32843053
[TBL] [Abstract][Full Text] [Related]
10. Plasma miR-1247-5p, miR-301b-3p and miR-105-5p as potential biomarkers for early diagnosis of non-small cell lung cancer.
Dong X; Chang M; Song X; Ding S; Xie L; Song X
Thorac Cancer; 2021 Feb; 12(4):539-548. PubMed ID: 33372399
[TBL] [Abstract][Full Text] [Related]
11. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
12. MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS.
Fan Q; Hu X; Zhang H; Wang S; Zhang H; You C; Zhang CY; Liang H; Chen X; Ba Y
Cell Physiol Biochem; 2017; 44(4):1311-1324. PubMed ID: 29183007
[TBL] [Abstract][Full Text] [Related]
13. Circulating microRNAs as novel biomarkers of ALK-positive nonsmall cell lung cancer and predictors of response to crizotinib therapy.
Li LL; Qu LL; Fu HJ; Zheng XF; Tang CH; Li XY; Chen J; Wang WX; Yang SX; Wang L; Zhao GH; Lv PP; Zhang M; Lei YY; Qin HF; Wang H; Gao HJ; Liu XQ
Oncotarget; 2017 Jul; 8(28):45399-45414. PubMed ID: 28514730
[TBL] [Abstract][Full Text] [Related]
14. miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer.
Zhong S; Golpon H; Zardo P; Borlak J
Transl Res; 2021 Apr; 230():164-196. PubMed ID: 33253979
[TBL] [Abstract][Full Text] [Related]
15. Circulating miR-21-5p and miR-126-3p: diagnostic, prognostic value, and multivariate analysis in non-small-cell lung cancer.
Soliman SE; Abdelaleem AH; Alhanafy AM; Ibrahem RAL; Elhaded ASA; Assar MFA
Mol Biol Rep; 2021 Mar; 48(3):2543-2552. PubMed ID: 33837901
[TBL] [Abstract][Full Text] [Related]
16. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.
Giray BG; Emekdas G; Tezcan S; Ulger M; Serin MS; Sezgin O; Altintas E; Tiftik EN
Mol Biol Rep; 2014 Jul; 41(7):4513-9. PubMed ID: 24595450
[TBL] [Abstract][Full Text] [Related]
17. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
18. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
[TBL] [Abstract][Full Text] [Related]
19. Serum miR-1228-3p and miR-181a-5p as Noninvasive Biomarkers for Non-Small Cell Lung Cancer Diagnosis and Prognosis.
Xue WX; Zhang MY; Rui Li ; Liu X; Yin YH; Qu YQ
Biomed Res Int; 2020; 2020():9601876. PubMed ID: 32724822
[TBL] [Abstract][Full Text] [Related]
20. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
